Diagnostic Approach to Unexplained Cardiac Arrest (from the FIVI-Gen Study)
Juan Jiménez-Jáimez1, Rafael Peinado2, Esther Zorio Grima3
1Cardiology Clinical Management Unit, Granada University Hospitals, Granada Institute of Biohealth Research, Granada, Spain.
Insights
A new diagnostic protocol successfully identified genetic channelopathies in about half of unexplained cardiac arrest (UCA) cases. Genetic testing proved useful even without clear physical symptoms, aiding UCA diagnosis.
Area of Science:
- Cardiology
- Genetics
- Clinical Diagnostics
Background:
- Unexplained cardiac arrest (UCA) can stem from low-penetrance genetic disorders.
- A systematic diagnostic approach is needed to identify these underlying causes.
Purpose of the Study:
- To evaluate a novel sequential diagnostic protocol for identifying channelopathies in UCA patients.
- To assess the utility of pharmacologic testing and genetic sequencing in UCA diagnosis.
Main Methods:
- A cross-sectional study involving 35 UCA patients from 9 Spanish centers.
- Initial exclusion of structural/electrical heart disease via ECG, echocardiogram, and catheterization.
- Pharmacologic challenge tests (epinephrine, flecainide), family screening (ECG, echocardiogram), and next-generation sequencing (126 genes) if initial tests were negative.
Main Results:
- A firm diagnosis was established in 18 patients (51.4%).
- Diagnoses included Brugada syndrome (7), catecholaminergic polymorphic ventricular tachycardia (5), long QT syndrome (3), early repolarization syndrome (2), and short QT syndrome (1).
- Pharmacologic testing was the most common diagnostic method; genetic testing alone diagnosed 5 cases without clear phenotypes.
Conclusions:
- The sequential diagnostic protocol effectively diagnoses channelopathies in approximately half of UCA cases.
- Low clinical penetrance channelopathies are significant contributors to UCA.
- Careful interpretation of genetic tests can aid UCA diagnosis, even in the absence of a distinct phenotype.
Abstract:
Unexplained cardiac arrest (UCA) can be caused by low-penetrance genetic disorders. The aim of this cross-sectional study is to assess the usefulness of a new diagnostic protocol: Thirty-five patients were recruited from 9 Spanish centers. Electrocardiogram, echocardiogram, and coronary catheterization were used to rule out electrical or structural heart disease in all subjects. Patients underwent pharmacologic tests with epinephrine and flecainide, followed by assessment of family members using electrocardiogram and echocardiogram, and next-generation genetic sequencing to analyze 126 genes if all the other test results were negative. A firm diagnosis of channelopathy required phenotypic proof of the condition in unmasking tests, the presence of a pathogenic variant consistent with the phenotype observed, and/or co-segregation of the mutation found in a family member's phenotype. A firm diagnosis was made in 18 cases. The diagnoses were 7 Brugada syndrome, 5 catecholaminergic polymorphic ventricular tachycardia, 3 long QT syndrome, 2 early repolarization syndrome, and 1 short QT syndrome. Pharmacologic testing was the most frequent method of diagnosis. In 5 cases, the diagnosis was made based on positive genetic testing without phenotypic alterations. In conclusion, this sequential diagnostic protocol allows diagnoses to be made in approximately half of the UCA cases. These diagnoses are low clinical penetrance channelopathies. If interpreted carefully, genetic tests can be a useful tool for diagnosing UCA without a phenotype.
Related Concept Videos
Acute Coronary Syndrome III: Diagnostic Studies
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Dysrhythmias V: Evaluating Dysrhythmias
Heart Failure IV: Classification and Diagnostic Evaluation
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Mechanism of Cardiac Arrhythmias


